Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6 by Barozzi, Patrizia et al.
lable at ScienceDirect
Clinical Microbiology and Infection 22 (2016) 893e895Contents lists avaiClinical Microbiology and Infection
journal homepage: www.cl inicalmicrobiologyandinfect ion.comLetter to the Editor
Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in
individuals with chromosomally integrated HHV6Dear Sir,
Strenger et al. [1] have recently reported that, in individuals with
chromosomally integrated human herpes virus 6 (ciHHV6), a sig-
nificant emergence of HHV6 (U54 protein) -specific immune re-
sponses (mainly interferon-g (IFN-g)-producing CD8þ effector
memory T lymphocytes) can be observed after short-term periph-
eral blood mononuclear cell expansion, namely 9-day culture with
interleukin-2 (IL-2) and IL-7 proliferative cytokines, using U54-
derived peptides as antigenic stimulation. We read with interest
the authors' speculations, that this finding represents, first, a
further (indirect) evidence of active viral protein expression in
ciHHV6þ individuals, and that, in turn, such increased T-cell cyto-
toxic responses against HHV6 antigen-bearing cells could be
implied in autoimmune-like pathological features, speculatively
associated with ciHHV6. Here we briefly report and discuss our
immunological data observed in another series of individuals
with or without ciHHV6, obtained by performing similar antigen-
specific assays (for U54 and U90 HHV6 proteins), but using not-
expanded peripheral blood mononuclear cell samples to directly
investigate the frequencies of circulating HHV6-specific T cells.
After approval by the local ethics committee (protocol no. 1835-
63/11) and having obtained informed consent, we collected and
analysed one to five peripheral blood samples from 12 proven
ciHHV6þ subjects (described in Table 1) and from 27 ciHHV6-
negative HHV6-seropositive healthy controls (total of 30 and 31
samples tested, respectively). We performed both IFN-g-Elispot
assay (Mabtech, Nacka Strand, Sweden) and flow cytometry-
based cytokine secretion assays (CSA; Miltenyi Biotech, Bologna,
Italy) for different cytokines (IFN-g, tumour necrosis factor-a
(TNF-a), IL-2, IL-10, each also with memory T-cell profiling for
CD62L/CCR7 expression, as previously reported) [2,3], using uncul-
tured peripheral blood mononuclear cells stimulated for 18 h (IFN-
g-Elispot) or 3 h (CSA) with HHV6-specific peptide pools (PepMix,
JPT, Berlin, Germany), derived from either U54 (tegument protein)
or U90 (immediate early protein). Both assays were performed ac-
cording to the manufacturer's instructions and as previously
described [2,3]. For all cases and controls, at least one blood sam-
ple was analysed by IFN-g-Elispot and by CSA for all the cytokines
mentioned above (except for TNF-a in the control group).
Main results of the immunological analyses are summarized in
Table 2. In general, our data clearly show that HHV6-specific T lym-
phocytes are also readily measurable in the blood of ciHHV6þ indi-
viduals, without ex vivo T-cell expansion. In particular, U54-specifichttp://dx.doi.org/10.1016/j.cmi.2016.07.006
1198-743X/© 2016 European Society of Clinical Microbiology and Infectious Diseases. PuIFN-gþ T cells were detectable at least in one sample from 11 out of
12 ciHHV6þ subjects (92%). Moreover, in line with data reported by
Strenger et al. [1], other U54-specific cytokine-producing T-cell re-
sponses were also detectable, although less frequently (TNF-a: five
out of seven ciHHV6þ cases available for analysis, 71%; IL-2: two of
six, 33%; IL-10: four of six, 66%) and at lower magnitudes (Table 2).
However, according to both Elispot and CSA methods, the fre-
quencies of circulating U54-specific IFN-gþ T cells were not signif-
icantly different between the ciHHV6þ group and ciHHV6
controls. Also, with regard to U90-specific analyses, we detected
positive samples in most ciHHV6þ individuals (10/11, 91%), again
without a significant increase in the magnitude of IFN-gþ re-
sponses, compared with ciHHV6 controls. Of note, towards both
U54 and U90, median values of the specific IFN-g-producing T cells
tended to be even higher (about two- to three-fold) in the control
group (Table 2). Interestingly, by comparison, in a series of ciHHV6
patients affected with HHV6-associated chronic/recurrent benign
lymphadenopathy, we showed very high mean magnitudes of
circulating IFN-gþ T lymphocytes specific to U54 (0.81%) and U90
(2.82%), and this is well consistent with the presence of an active
immune process linked to HHV6 reactivation from typical latency
[2].
Concerning IFN-gþ memory T-cell profiles, we also found that
CD62L effector memory CD8þ T lymphocytes, specific to either
U54 or U90, represented the prevalent circulating subsets in the
ciHHV6þ group. In particular, U90-specific IFN-gþ effector memory
CD8þ T cells constituted the only memory pool with a median
magnitude (0.27%) higher than in the control group (0.11%)
(p 0.393). Instead, in this latter group, CD8þ/CD62Lþ central mem-
ory appeared to be the prevalent phenotype of specific T-cell
response. Indeed, in agreement with the study by Strenger et al.
[1], it is conceivable that, upon antigen re-challenge, specific mem-
ory pools of circulating T cells with cytotoxic effector memory CD8þ
phenotype may be those able to promptly react and have a prolif-
erative burst.
We also demonstrated the presence of circulating T cells able to
secrete IL-10 after U54/U90 antigenic stimulation, so disclosing that
HHV6-specific suppressive responses may be revealed, at lower
magnitude, along with the cytotoxic ones.
Taken together, the findings by Strenger et al. [1] and by our
group suggest that, in ciHHV6þ individuals, HHV6-specific cyto-
toxic T-cell responses are significantly more reactive (i.e. more pro-
nouncedly expandable) upon specific prolonged stimulation,
whereas in basal conditions, these specific effector T cells are stillblished by Elsevier Ltd. All rights reserved.
Table 1
Main features of the enrolled individuals with proven chromosomally integrated human herpes virus 6 (ciHHV6)
ID no. Age Sex Integrated virus Site of integration Clinical information Family
1 40 M ciHHV6B 17p ter familial Mediterranean fever A
2 10 F ciHHV6B 17p ter healthy, daughter of no. 1 A
3 5 F ciHHV6B 17p ter healthy, daughter of no. 1 A
4 67 F ciHHV6B 17p ter healthy, mother of no. 1 A
5 71 M ciHHV6B 17p ter healthy, father of no. 1 A
6 49 M ciHHV6B 19p ter multiple sclerosis B
7 12 M ciHHV6B 19p ter healthy, son of no. 6 B
8 63 F ciHHV6B n.a. non-Hodgkin’s lymphoma C
9 88 M ciHHV6B n.a. Waldenstr€om macroglobulinaemia D
10 37 M ciHHV6A 17p ter retinitis pigmentosa E
11 61 M ciHHV6A 17p ter healthy, father of no. 10 E
12 68 M ciHHV6A n.a. myelodysplastic syndrome F
In this study, we analysed 12 individuals (mean age 47 years, range 5e88 years, M/F 4/8) with proven ciHHV6 by positive HHV6 PCR on hair follicles, according to HHV6 Foun-
dation recommendations (http://hhv-6foundation.org/clinicians/cihhv-6-testing), by using a commercially available diagnostic kit (Real Time Q-PCR, Nanogene, Milano, Italy)
[2]. In addition, the site of integration was investigated using fluorescent in situ hybridization (the fragments ZVB70 and ZVH14were used as probes) [4], and/or chromosome-
specific PCR with primers derived from subtelomere regions of chromosomes 2p, 11q, 17p, 18q and HHV-6 left/right direct repeats [5]. As controls, we analysed 27 HHV6
seropositive individuals (mean age 40 years old, range 10e77 years, M/F 10/17), in which ciHHV6 was excluded by negative HHV6 PCR on hair follicles. Abbreviation: n.a.,
not available (chromosomal integration not found in 2p, 11q, 17p, 18q).
Table 2
Main immunological data on circulating cytokine-producing T cells specific to human herpes virus 6 (HHV6) antigens (either U54 or U90 proteins) in individuals with











IFN-g SFCs/106 PBMCs 22 (8e242) 21 (8e60) 60 (10e1150) 55 (15e380)
Cytokine secretion assays
IFN-gþ T cells (%) CD4þ and CD8þ 0.15 (0.02e1.42) 0.17 (0.11e0.63) 0.26 (0.20e0.48) 0.63 (0.28e1.23)
CD4þ 0.07 (0.02e0.72) 0.12 (0.02e0.23) 0.12 (0.06e0.15) 0.26 (0.15e0.35)
CD8þ 0.17 (0.03e0.36) 0.16 (0.09e0.40) 0.26 (0.10e0.33) 0.51 (0.36e0.88)
CD4þ EM 0.04 (0.01e0.11) 0.03 (0.01e0.05) 0.09 (0.04e0.14) 0.12 (0.06e0.20)
CD4þ CM 0.04 (0.01e0.71) 0.10 (0.03e0.18) 0.03 (0.01e0.10) 0.13 (0.08e0.19)
CD8þ EM 0.14 (0.02e0.45) 0.27 (0.01e0.39) 0.17 (0.01e0.21) 0.11 (0.06e0.26)
CD8þ CM 0.02 (0.01e0.25) 0.08 (0.01e0.15) 0.11 (0.01e0.28) 0.45 (0.25e0.62)
IL-2þ T cells (%) CD4þ and CD8þ 0.02 (0.01e0.03) 0.03 (0.02e0.03) 0.04 (0.02e0.14) 0.12 (0.02e0.16)
TNF-aþ T cells (%) CD4þ and CD8þ 0.18 (0.05e0.74) 0.18 (0.06e0.18) n.d. n.d.
IL-10þ T cells (%) CD4þ and CD8þ 0.06 (0.03e0.06) 0.11 (0.04e0.19) 0.10 (0.04e0.24) 0.09 (0.06e0.17)
Median frequencies (and range) of responding T cells are separately reported for IFN-g-Elispot assay and CSA assays for different cytokines. Elispot results are expressed as
number of spot-forming cells (SFCs) out of 1million of peripheral bloodmononuclear cells (PBMCs). CSA results are expressed as percentages (%) of different functional subsets
out of total T lymphocytes (CD4þ and CD8þ), and out of total CD4þ or total CD8þ T cells. Statistical analyses were conducted using ManneWhitney U-test; p values <0.05 were
considered statistically significant. Comparisons of HHV6-specific T-cell frequencies between ciHHV6 positive and negative groups were not statistically significant (p >0.05)
for all subsets. No patients received specific treatment during 3months before the collections of blood samples used for immunological analyses. Abbreviations: n.d., not done;
EM, effector memory (CD62L, CCR7); CM, central memory (CD62Lþ, CCR7þ); IFN-g, interferon-g; IL-2, interleukin-2; TNF-a, tumour necrosis factor-a.
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seropositive subjects without viral integration. However, differ-
ences between these two studies could also be related to the use
of different immunological methods (intracellular staining versus
CSA and Elispot), as well as to variability between unrelated small
cohorts. These data well support the notion that a complete im-
mune tolerance toward HHV6, bymeans of classic thymic selection,
is not occurring in ciHHV6þ individuals. However, it is possible that,
in vivo, some peripheral tolerancemechanisms, such as thosemedi-
ated by regulatory T cell and T helper type 2 subsets, may act to
maintain harmless levels of ‘auto-reactive’ cytotoxic T cells target-
ing HHV6-derived epitopes, which are potentially exposed ubiqui-
tously in ciHHV6þ individuals. We speculate that the regulatory
arm of immunity could have a role in the prevention of excessive
immune activations against HHV6 antigen-bearing cells, which, in
turn, could be primarily involved in the development of various
autoimmune events possibly described in ciHHV6þ patients. Unfor-
tunately, when trying to identify distinct clinico-immunological
subgroups among ciHHV6þ individuals enrolled in our study, no
statistical analyses were feasible, due to the low number of cases.In conclusion, it would be interesting to compare frequencies
of HHV6-specific cytokine-producing T cells between ciHHV6þ
‘patients’ (with pathological conditions that are possibly
ciHHV6-related) and ciHHV6þ healthy individuals (with no asso-
ciated abnormalities), focusing on functional memory T-cell pro-
files reactive to different HHV6 antigens. Of course, larger
cohorts of ciHHV6þ individuals are required to address this issue,
also considering that ciHHV6 patients typically display transient
or subtle autoimmune-like features, which frequently remain un-
recognized and for which the triggers remain unknown. Clinico-
immunological monitoring should be set up to assess whether
an enhanced cytotoxic immunity against HHV6 antigens is detect-
able in a significant concomitance with pathological manifesta-
tions associated with ciHHV6.Transparency declaration
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